Tosoh Corporation has announced that it will be increasing the production capacity of its Toyopearl liquid chromatography separation and purification media at its Nanyo Complex, in Shunan, Yamaguchi Prefecture. The nearly 50% production capacity increase is in response to growing global demand for purification media from the antibody drug manufacturing industry.
At a cost of approximately ¥5 billion (about 42 million €), the Nanyo Complex’s Toyopearl production facilities are being expanded. Construction began in October 2016 and is slated for completion in August 2018. Commercial operations at the expanded production facilities are expected to commence in April 2019.
Liquid chromatography media are used in the production of biopharmaceuticals. Employing differences in charge, hydrophobicity, specific affinity, and molecular size, these media are designed to separate and purify target components. Given the rapid growth of the market for biopharmaceutical products, in Japan, the United States, countries in Europe and in China, India, and other emerging nations, these media are in high demand.
With its high strength, superior chemical stability, and high adsorption capacity, Toyopearl ranks among Tosoh’s bioscience operation’s leading products. It is well suited to the industrial-scale purification processes used by pharmaceutical and other companies for target ingredients. Tosoh has seen particularly strong demand for Toyopearl’s antibody drug purification from the biopharmaceutical industry.
With the expansion of its Toyopearl production capacity, Tosoh will be better positioned to respond to vigorous demand in the market for separation and purification media. Tosoh plans further expansions of the scale and profitability of its business going forward.